MLLStart! advised Clinical Research Ventures (CR Ventures), a Singapore, Frankfurt and Boston based global life-science investor with a focus on companies entering Phase I or II clinical trials in its investment into BioVersys AG, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics.
The investment forms part of the recently closed series B round and will allow BioVersys to advance its two lead assets for multi-drug resistant bacterial infections through initial clinical trials. In November BioVersys announced it had successfully dosed the first patients in its phase I trial with BV100.
The team was led by Senior Associate Marco Fusi (Transaction/M&A & Venture Capital) and supported by Karin Oberlin (Partner, Transaction/M&A & Venture Capital) and included Julian Kläser (Senior Associate, Tax) and Göktug Gürbüz (Junior Associate).